Oncology Institute Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療服務供應商行業排名48/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價6.50。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Oncology Institute Inc評分
相關信息
行業排名
48 / 78
全市場排名
204 / 4578
所屬行業
醫療服務供應商
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
買入
評級
6.500
目標均價
+104.40%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Oncology Institute Inc亮點
亮點風險
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
公司代碼TOI
公司Oncology Institute Inc
CEOVirnich (Daniel)
網址https://theoncologyinstitute.com/
常見問題
Oncology Institute Inc(TOI)的當前股價是多少?
Oncology Institute Inc(TOI)的當前股價是 3.390。
Oncology Institute Inc 的股票代碼是什麼?
Oncology Institute Inc的股票代碼是TOI。
Oncology Institute Inc股票的52週最高點是多少?
Oncology Institute Inc股票的52週最高點是4.880。
Oncology Institute Inc股票的52週最低點是多少?
Oncology Institute Inc股票的52週最低點是0.193。
Oncology Institute Inc的市值是多少?
Oncology Institute Inc的市值是330.76M。
Oncology Institute Inc的淨利潤是多少?
Oncology Institute Inc的淨利潤為-53.01M。
現在Oncology Institute Inc(TOI)的股票是買入、持有還是賣出?
根據分析師評級,Oncology Institute Inc(TOI)的總體評級為買入,目標價格為6.500。
Oncology Institute Inc(TOI)股票的每股收益(EPS TTM)是多少
Oncology Institute Inc(TOI)股票的每股收益(EPS TTM)是-0.634。